Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms

Active Cooperative Agreement Awarded Last action

Award ID
U01CA200466
Recipient
Awarding agency
Obligated
$22,339,044

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date 88% complete
Originally
Funding
  • $21,721,591.95 Federal
  • $617,452.00 Non-federal
Place of performance
Pittsburgh, PA 15222, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $1,263,696 $0
Amendment $126,433 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,137,892 $0
Amendment $1,137,892 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $63,216 $0
Amendment $63,216 $0
Amendment $63,216 $0
Amendment $63,216 $0
Amendment $63,216 $0
Amendment $1,137,893 $0
Amendment $1,137,893 $0
Amendment $1,137,893 $0
Amendment $1,137,893 $0
Amendment $1,137,893 $0
Amendment $1,137,893 $0
Amendment $915,566 $0
Amendment $915,566 $0
Amendment $915,566 $0
Amendment $915,566 $0
Amendment -$4,609 $0
Amendment -$4,609 $0
Amendment Validation of biomarkers for risk prediction and early diagnosis of pancreatic adenocarcinoma - description (provided by applicant): a majority of pancreatic… -$4,609 $0
Amendment -$4,609 $0
Amendment Validation of biomarkers for risk prediction and early diagnosis of pancreatic adenocarcinoma - description (provided by applicant): a majority of pancreatic… -$4,609 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $617,452 $0
Amendment $617,452 $617,452
Amendment $0 $0
Amendment $0 $0
Amendment $875,414 $0
Amendment $0 $0
Amendment $0 $0
Amendment $857,224 $0
Amendment $0 $0
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Subawards

Subrecipient Amount Awarded
Board Of Regents Of The University Of Nebraska Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma $460,500
Board Of Regents Of The University Of Nebraska responsible for biomarkers (MUC5AC and MUC4) validation in serum samples proposed in Aim 1 and Aim 2. $546,660
Van Andel Research Institute execute and further develop, as necessary, the analytic strategies outlined in the proposal. $448,889
Board Of Regents Of The University Of Nebraska Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma $153,500
Van Andel Research Institute $48,000
Board Of Regents Of The University Of Nebraska $265,655
The Leland Stanford Junior University Validation of biomarkers for early diagnosis and risk prediction of pancreatic neoplasms $5,440
Van Andel Research Institute $95,161
Board Of Regents Of The University Of Nebraska $280,689
The Leland Stanford Junior University $19,200
Board Of Regents Of The University Of Nebraska $0
Van Andel Research Institute $95,162
Board Of Regents Of The University Of Nebraska $112,875
Board Of Regents Of The University Of Nebraska Validation of biomarkers for early diagnosis and risk prediction of pancreatice neoplasms $280,689
The Regents Of The University Of California. San Francisco Development of a Tissue Microarray Resource for Pancreatic Cancer Biomarker Research $3,320
Board Of Regents Of The University Of Nebraska The program will be coordinated at UNMC by Dr. Batra. His group will be responsible for biomarkers (MUC5AC and MUC4) validation in serum samples proposed in Aim… $280,689
The Johns Hopkins University We plan to undertake pancreatic cyst fluid analysis in a blinded fashion of samples provided by the PCDC pancreatic cyst group. We will perform ddPCR analysis… $32,359
The Washington University In an ongoing, multicenter validation study including 142 patients with peri-surgically aspirated cyst fluid consisting of 39 non-mucinous lesions, 42 MCNs, and… $3,799
The Leland Stanford Junior University Specific work will include: 1. Identify eligible pancreatic cyst samples within Dr. Park’s cyst repository for sharing with other Co-Investigators in this… $22,960
The Regents Of The University Of California. San Francisco Proteases mediate a number of critical cancer processes including invasion, proliferation, and metastageneisis1,2. Protease expression is uniquely altered in… -$15,495
Van Andel Research Institute The laboratory of Dr. Haab will validate biomarkers discovered in previous research. The biomarkers are found in the cyst fluid and are proposed to accurately… $125,304
The Washington University In an ongoing, multicenter validation study including 142 patients with peri-surgically aspirated cyst fluid consisting of 39 non-mucinous lesions, 42 MCNs, and… $78,525
The Johns Hopkins University We plan to undertake pancreatic cyst fluid analysis in a blinded fashion of samples provided by the PCDC pancreatic cyst group. We will perform ddPCR analysis… $101,250
The Regents Of The University Of California. San Francisco Proteases mediate a number of critical cancer processes including invasion, proliferation, and metastageneisis1,2. Protease expression is uniquely altered in… $86,998
Board Of Regents Of The University Of Nebraska The program will be coordinated at UNMC by Dr. Batra. His group will be responsible for biomarkers (MUC5AC and MUC4) validation in serum samples proposed in Aim… $561,378
Georgetown University Task 1. Recruitment of patient volunteers and collection of fluids per SOP. Georgetown University will serve as a subsite in this multicenter study to assist in… -$11,120
The Leland Stanford Junior University Specific work will include: 1. Identify eligible pancreatic cyst samples within Dr. Park’s cyst repository for sharing with other Co-Investigators in this… $32,500
The Johns Hopkins University We plan to undertake pancreatic cyst fluid analysis in a blinded fashion of samples provided by the PCDC pancreatic cyst group. We will perform ddPCR analysis… $19,500
The Regents Of The University Of California Patients with pancreatic cysts eligible for this study will be identified in the gastroenterology, pancreatic cyst, and surgical oncology clinics by Dr.… -$22,000
The Ohio State University Patients with pancreatic cysts eligible for this study will be identitifed in the gastroenterology clinic, multidisciplinary pancreatic tumor clinic, surgery… -$21,994
Van Andel Research Institute The laboratory of Dr. Haab will validate biomarkers discovered in previous research. The biomarkers are found in the cyst fluid and are proposed to accurately… $13,316
Board Of Regents Of The University Of Nebraska The program will be coordinated at UNMC by Dr. Batra. His group will be responsible for biomarkers (MUC5AC and MUC4) validation in serum samples proposed in Aim… $39,356
Show all 32

Quick answers

Who received award U01CA200466?

U01CA200466 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Cancer Institute (National Institutes of Health) on May 17, 2016.

How much is award U01CA200466 worth?

$22,339,044 has been obligated on U01CA200466: $21,721,592 in federal funding and $617,452 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login